Janssen-Cilag S.p.A.
19
2
3
14
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 19 trials
100.0%
+13.5% vs industry average
21%
4 trials in Phase 3/4
14%
2 of 14 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (19)
Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.
Role: collaborator
Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance
Role: collaborator
A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or Selexipag
Role: lead
A Study to Describe Routine Treatment Pathways in Participants With Major Depression and Active Suicidal Ideation With Intent in Italy
Role: lead
A "Physician & Patient-powered" Cohort Registry (MY MYELOMA)
Role: collaborator
An Italian Observation of Antiretroviral Treatment in Participants Taking Darunavir/ Cobicistat Plus Emtricitabine and Tenofovir Alafenamide Fumarate
Role: lead
A Study of Guselkumab in Naive or Bio-experienced Participants With Regional (Facial and Genital) Psoriasis
Role: lead
A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting
Role: lead
A Study in Participants With a Newly Confirmed Diagnosis of Spondyloarthritis (SpA) Who Are New to Conventional, Targeted and Biological DMARDs
Role: lead
Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive
Role: collaborator
Study in HIV1-Positive, Virosuppressed Patients Currently inTreatment With Ritonavir-Boosted Protease Inhibitors (PI/r) Starting Cobicistat-Boosted Darunavir (DRV/c - Rezolsta)
Role: lead
Survey on QUality of Life In myeloDisplasia (SQUID)
Role: lead
An Immunologic Study of Treatment-Naive HIV Patients Starting a Darunavir/Ritonavir- or Efavirenz-Based HAART
Role: lead
A Study to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected Patients
Role: lead
Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder
Role: lead
Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years
Role: lead
Non-interventional Study on Use of Darunavir With Ritonavir in Clinical Practice
Role: lead
VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)
Role: collaborator
A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's Disease
Role: lead
All 19 trials loaded